PAM
SUPN icon

PVG Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

PVG Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,935
Closed -$398K – 73
2021
Q2 		$398K Buy
+12,935
New +$397K 1.24% 24

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

PVG Asset Management's SUPN Position: Q3 2021 in Review

PVG Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 12,935 shares — an estimated $398K sold.

PVG Asset Management first reported a position in SUPN in Q2 2021 and held it in 1 quarter. The position peaked at $398K in Q2 2021. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • PVG Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • PVG Asset Management sold 12,935 Supernus Pharmaceuticals shares in Q3 2021, an estimated $398K.
  • PVG Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • PVG Asset Management's Supernus Pharmaceuticals position peaked at $398K in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on PVG Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.